T o implant or not to implant a primary prevention implantable-cardioverter defibrillator (ICD) in older patients is a question that has challenged clinicians for years. On the one hand, the ICD is a highly effective therapy for the prevention of sudden cardiac death. On the other hand, there are no definitive data regarding the benefit of the ICD in older patients. Indeed, in the pivotal randomized clinical trials that demonstrated the efficacy of the ICD, the mean or median age of enrolled patients was well below 75 years of age (1) (2) (3) (4) . There are reasons why older patients may not derive survival benefit from the ICD.
Such patients typically have heart failure along with other comorbidities that may attenuate the efficacy of the ICD. Older patients may also be frail, and this, along with the coexisting diseases, may make the device implantation risky and negatively impact their quality of life, raising concerns about therapies, like the ICD, that prolong life but do not necessarily improve its quality. However, when the ICD is coupled with cardiac resynchronization therapy (CRT), there is potential for improved quality of life and reduced heart failure hospitalizations, 2 important goals in the care of heart failure patients.
In the main randomized clinical trials of CRTdefibrillator (CRT-D) or CRT-pacemaker (CRT-P), the relatively young age of enrolled patients is noticeable, with a mean age ranging from 64 to 68 years (5-8).
As expected, their level of comorbidity was lower than that seen in the average older patient. As such, it is reasonable to wonder whether the results of those trials can be extrapolated to older patients.
Although several investigations suggested an association between CRT and improved echocardiographic and/or clinical outcomes in older patients (9-13), most results were limited by the relatively small sample of older patients (9) (10) (11) (12) , and some results were limited by the retrospective analysis (10) (11) (12) . Those studies were not a priori designed to examine survival or heart failure hospitalization in older patients nor were they statistically powered to do so (9-13). Therefore, in those studies, the similar survival observed between older patients and that of their younger counterparts is possibly due to the lack of adequate statistical power and should not be interpreted as a proof of survival benefit of CRT in the elderly. Although some of these studies examined New York Heart Association (NYHA) functional class before and after CRT (10-13), only a minority used robust and validated tools to assess quality of life (13) . 
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